Plain-English translation of NCT02531113 on ClinicalTrials.gov ↗ · Source last updated · Translation generated · How we translate trials
Read our Crohn's disease research guide →Phase 2 — Testing in a bigger group (up to a few hundred people) to see if the treatment actually works and is still safe.
This trial studied whether , an oral medication taken by mouth, could help people with moderate to severe Crohn's disease whose condition was not controlled by other treatments. Researchers examined whether the medication could reduce inflammation in the intestines and improve how the bowel looked during endoscopy exams. The trial involved two stages: an initial 12-week treatment period followed by an optional 100-week continuation period for those who benefited.
Crohn's disease is a serious inflammatory bowel condition that doesn't respond adequately to currently available treatments in some patients. This trial aimed to see whether this new medication could offer a better option for people whose disease remained active despite trying other therapies.
Participants received the oral medication daily during a 12-week initial treatment period and had their progress monitored through clinical assessments and endoscopy examinations to check for intestinal healing. Those who responded well to treatment were invited to continue taking the medication for up to an additional 100 weeks while researchers continued to track how they were doing. Throughout the trial, blood and tissue samples were collected to measure markers of inflammation and healing.
AI-generated summary from trial data · Sep 24, 2026 · Not medical advice
United States